Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Ribociclib”

169 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 169 results

Early research (Phase 1)Study completedNCT02370706
What this trial is testing

Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis

Who this might be right for
Myelofibrosis
Novartis Pharmaceuticals 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT03090165
What this trial is testing

Ribociclib and Bicalutamide in AR+ TNBC

Who this might be right for
Triple Negative Breast Cancer
Kari Wisinski 37
Testing effectiveness (Phase 2)Looking for participantsNCT06375707
What this trial is testing

Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 144
Large-scale testing (Phase 3)Ended earlyNCT03905343
What this trial is testing

Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC

Who this might be right for
Breast Cancer
Swiss Cancer Institute 25
Early research (Phase 1)Study completedNCT01898845
What this trial is testing

A Phase I Study of LEE011 in Asian Patients

Who this might be right for
Advanced Solid Tumors
Novartis Pharmaceuticals 17
Large-scale testing (Phase 3)Active Not RecruitingNCT04964934
What this trial is testing

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

Who this might be right for
ER-Positive HER2-Negative Breast Cancer
AstraZeneca 315
Early research (Phase 1)Active Not RecruitingNCT02608216
What this trial is testing

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

Who this might be right for
Breast NeoplasmMetastatic Breast CancerRb+ Breast Cancer
University of Pennsylvania 20
Not applicableLooking for participantsNCT06344416
What this trial is testing

Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform

Who this might be right for
Any Solid Oral Medication
Dosentrx Ltd. 200
Not applicableStudy completedNCT07512063
What this trial is testing

Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 480
Large-scale testing (Phase 3)Not Yet RecruitingNCT06996093
What this trial is testing

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

Who this might be right for
Breast Cancer
Fudan University 2,508
Not applicableStudy completedNCT07148505
What this trial is testing

Real-world Outcomes Among Patients Treated With Ribociclib

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 373
Not applicableActive Not RecruitingNCT05697146
What this trial is testing

Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 1,019
Early research (Phase 1)Study completedNCT02586675
What this trial is testing

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

Who this might be right for
Breast CancerBreast Cancer - FemaleBreast Cancer - Male
H. Lee Moffitt Cancer Center and Research Institute 7
Large-scale testing (Phase 3)Looking for participantsNCT07085767
What this trial is testing

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Who this might be right for
Breast CancerLocally Advanced Breast CancerMetastatic Breast Cancer+2 more
Olema Pharmaceuticals, Inc. 1,000
Early research (Phase 1)Study completedNCT02431481
What this trial is testing

Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011

Who this might be right for
Normal Renal FunctionImpaired Renal Function
Novartis Pharmaceuticals 38
Testing effectiveness (Phase 2)Ended earlyNCT02524119
What this trial is testing

LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
University of Texas Southwestern Medical Center 5
Large-scale testing (Phase 3)Study completedNCT03462251
What this trial is testing

Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line

Who this might be right for
Breast CancerHormone Receptor Positive TumorHER 2 Negative Breast Cancer
iOMEDICO AG 41
Testing effectiveness (Phase 2)Active Not RecruitingNCT03285412
What this trial is testing

CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer

Who this might be right for
Breast Cancer
Massachusetts General Hospital 120
Very early researchEnded earlyNCT03179956
What this trial is testing

Impact of Ribociclib on Head and Neck Squamous Cell Cancer

Who this might be right for
Squamous Cell Carcinoma of the Head and Neck
Fox Chase Cancer Center 1
Not applicableLooking for participantsNCT06830720
What this trial is testing

A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence

Who this might be right for
Breast Neoplasms
Novartis Pharmaceuticals 3,250
Load More Results